Rationale for PARP inhibitor combinations for advanced prostate cancer - Conversation 1

touchMDT for touchONCOLOGY Listen to an oncology pharmacist and a medical oncologist discuss the rationale for PARP inhibitors for the treatment of advanced prostate cancer.  The multidisciplinary team  Oncology Pharmacist: Dr Lisa Holle, USA Medical Oncologist: Dr Wassim Abida, USA This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/